Which has higher earnings & valuation, TRVN or SCPS?

Scopus BioPharma has lower revenue, but higher earnings than Trevena. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevena $443K 0.00 -$40.29M -$47.04 N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Is TRVN or SCPS more profitable?

Company Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% Scopus BioPharma N/A N/A N/A

Is TRVN or VRPX more profitable?

Trevena's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Trevena N/A N/A -119.55% Virpax Pharmaceuticals N/A -1,554.34% -338.29%

Is SYRS or TRVN more profitable?

Trevena's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Syros Pharmaceuticals N/A -3,369.56% -97.04% Trevena N/A N/A -119.55%

Is NAVB or TRVN more profitable?

Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Trevena N/A N/A -119.55%

Is PXMD or TRVN more profitable?

Trevena's return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Trevena N/A N/A -119.55%

Trevena (TRVN) Competitors

$0.0015 -0.01 (-86.49%)

As of 06/24/2026 03:58 PM Eastern

Compare

TRVN vs. SCPS, VRPX, SYRS, NAVB, and PXMD

Should you buy Trevena stock or one of its competitors? MarketBeat compares Trevena with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Trevena include Scopus BioPharma (SCPS), Virpax Pharmaceuticals (VRPX), Syros Pharmaceuticals (SYRS), Navidea Biopharmaceuticals (NAVB), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry.

How does Trevena compare to Scopus BioPharma?

Trevena (NASDAQ:TRVN) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

13.6% of Trevena shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Scopus BioPharma has lower revenue, but higher earnings than Trevena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

Trevena has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market.

In the previous week, Trevena had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Scopus BioPharma. Trevena's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Trevena	Neutral
Scopus BioPharma	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
Scopus BioPharma	N/A	N/A	N/A

Summary

Trevena beats Scopus BioPharma on 4 of the 7 factors compared between the two stocks.

How does Trevena compare to Virpax Pharmaceuticals?

Trevena (NASDAQ:TRVN) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

In the previous week, Trevena had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Virpax Pharmaceuticals. Trevena's average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Trevena	Neutral
Virpax Pharmaceuticals	Neutral

Trevena's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevena	N/A	N/A	-119.55%
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%

Virpax Pharmaceuticals has lower revenue, but higher earnings than Trevena. Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A

13.6% of Trevena shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Trevena has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market.

Summary

Trevena beats Virpax Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Trevena compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Trevena had 1 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Syros Pharmaceuticals. Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
Syros Pharmaceuticals	Neutral
Trevena	Neutral

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Trevena has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386K	0.01	-$164.57M	-$3.03	N/A
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A

Trevena's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
Trevena	N/A	N/A	-119.55%

Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Trevena has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

Summary

Syros Pharmaceuticals beats Trevena on 6 of the 11 factors compared between the two stocks.

How does Trevena compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Trevena had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Trevena	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Trevena has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A

Summary

Navidea Biopharmaceuticals beats Trevena on 5 of the 9 factors compared between the two stocks.

How does Trevena compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Trevena had 1 more articles in the media than PaxMedica. MarketBeat recorded 1 mentions for Trevena and 0 mentions for PaxMedica. PaxMedica's average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Trevena	Neutral

PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Trevena has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 1.0% of PaxMedica shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Trevena's return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Trevena	N/A	N/A	-119.55%

PaxMedica has higher earnings, but lower revenue than Trevena. PaxMedica is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A

Summary

Trevena beats PaxMedica on 8 of the 10 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

TRVN vs. The Competition

Export

Metric	Trevena	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1K	$935.75M	$6.74B	$12.32B
Dividend Yield	N/A	4.84%	2.68%	5.88%
P/E Ratio	0.00	1.44	25.14	23.95
Price / Sales	0.00	117.32	534.57	107.90
Price / Cash	N/A	20.06	45.29	53.76
Price / Book	0.00	7.78	10.79	6.41
Net Income	-$40.29M	-$4.18M	$3.56B	$337.14M
7 Day Performance	N/A	0.89%	0.99%	-1.07%
1 Month Performance	N/A	1.95%	0.80%	0.48%
1 Year Performance	N/A	46.36%	30.27%	28.42%

Trevena Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRVN Trevena	N/A	$0.00 -86.5%	N/A	-99.9%	$1K	$443K	N/A	40	Gap Down
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	+33.3%	$17K	N/A	N/A	9
VRPX Virpax Pharmaceuticals	N/A	$0.01 flat	N/A	N/A	$14K	N/A	N/A	7
SYRS Syros Pharmaceuticals	N/A	$0.00 +300.0%	N/A	-99.6%	$11K	$386K	N/A	120	High Trading Volume
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRVN) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trevena (TRVN) Competitors

TRVN vs. SCPS, VRPX, SYRS, NAVB, and PXMD

How does Trevena compare to Scopus BioPharma?

Summary

How does Trevena compare to Virpax Pharmaceuticals?

Summary

How does Trevena compare to Syros Pharmaceuticals?

Summary

How does Trevena compare to Navidea Biopharmaceuticals?

Summary

How does Trevena compare to PaxMedica?

Summary

New MarketBeat Followers Over Time

TRVN vs. The Competition

Trevena Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trevena (TRVN) Competitors

TRVN vs. SCPS, VRPX, SYRS, NAVB, and PXMD

How does Trevena compare to Scopus BioPharma?

Do insiders and institutionals have more ownership in TRVN or SCPS?

Which has higher earnings & valuation, TRVN or SCPS?

Which has more volatility & risk, TRVN or SCPS?

Does the media favor TRVN or SCPS?

Is TRVN or SCPS more profitable?

Summary

How does Trevena compare to Virpax Pharmaceuticals?

Does the media favor TRVN or VRPX?

Is TRVN or VRPX more profitable?

Which has higher earnings & valuation, TRVN or VRPX?

Do insiders and institutionals have more ownership in TRVN or VRPX?

Which has more volatility & risk, TRVN or VRPX?

Summary

How does Trevena compare to Syros Pharmaceuticals?

Does the media refer more to SYRS or TRVN?

Do institutionals and insiders believe in SYRS or TRVN?

Which has higher valuation and earnings, SYRS or TRVN?

Is SYRS or TRVN more profitable?

Which has more volatility & risk, SYRS or TRVN?

Summary

How does Trevena compare to Navidea Biopharmaceuticals?

Do institutionals and insiders hold more shares of NAVB or TRVN?

Does the media favor NAVB or TRVN?

Is NAVB or TRVN more profitable?

Which has more risk and volatility, NAVB or TRVN?

Which has stronger valuation & earnings, NAVB or TRVN?

Summary

How does Trevena compare to PaxMedica?

Does the media favor PXMD or TRVN?

Which has more risk & volatility, PXMD or TRVN?

Do insiders and institutionals believe in PXMD or TRVN?

Is PXMD or TRVN more profitable?

Which has better valuation & earnings, PXMD or TRVN?

Summary

New MarketBeat Followers Over Time

TRVN vs. The Competition

Trevena Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools